Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis of the phase III ARISTOTLE trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published Date:

Abstract

BACKGROUND: Neoadjuvant chemoradiotherapy is a standard treatment for locally advanced rectal cancer, but acute diarrhoea remains a significant side effect, affecting the completion of chemoradiotherapy treatment.

Authors

  • Ying Zhang
    Department of Nephrology, Nanchong Central Hospital Affiliated to North Sichuan Medical College, Nanchong, China.
  • Douglas Brand
    Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
  • Zhuoyan Shen
    Department of Medical Physics and Biomedical Engineering, University College London, London, UK. zhuoyan.shen.18@ucl.ac.uk.
  • Mikaël Simard
  • Sumeet Hindocha
    Division of Radiotherapy and Imaging, the Institute of Cancer, London, SM2 5NG, UK.
  • Olivia Chohan
    Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London WC1E 6BT, United Kingdom; University College London Hospitals NHS Foundation Trust, Radiotherapy Physics, 250 Euston Road, London NW1 2PG, United Kingdom.
  • Andre Lopes
    University College London, Cancer Institute, London, United Kingdom.
  • Rubina Begum
    Cancer Research & University College London Clinica Trial Unit, London, United Kingdom.
  • Nicholas West
    Leeds Institute of Medical Research, University of Leeds, LS9 7TF, UK.
  • Ane Appelt
    Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; Department of Medical Physics, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • Alexandra Gilbert
    Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, United Kingdom; Radiotherapy Research Group, Leeds Institute of Medical Research, University of Leeds, United Kingdom.
  • Elizabeth Miles
    National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, UK.
  • Tim Maughan
    Department of Oncology, University of Oxford, Oxford, UK.
  • David Sebag-Montefiore
    Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, United Kingdom; Radiotherapy Research Group, Leeds Institute of Medical Research, University of Leeds, United Kingdom.
  • Maria A Hawkins
    Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
  • Charles-Antoine Collins Fekete
    Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London WC1E 6BT, United Kingdom.

Keywords

No keywords available for this article.